Morgan Stanley initiated coverage of Novo Nordisk with an Overweight rating and $120 price target. The analyst added six American depository receipts to the firm’s European Union Pharmaceuticals coverage. The stock’s fundamental views are fully aligned with those the firm has on the underlying stocks, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Novo Nordisk, Eli Lilly, others raise prices of hundreds of drugs, WSJ reports
- Novo Nordisk price target raised to DKK 800 from DKK 730 at Morgan Stanley
- Novo Nordisk upgraded to Neutral from Sell at UBS
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/15/2024